Many NSML mutations result in low or no catalytic activity but also cause large conformational changes that enhance binding to MPZL1/Pzr, a driver of hypertrophic cardiomyopathy through the Akt and NF-κB pathways25. Here, MPZL1 is linked to hypertrophic cardiomyopathy.